Literature DB >> 20633539

MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.

Lei Shi1, Jian Chen, Jian Yang, Tianhong Pan, Shuguang Zhang, Zhimin Wang.   

Abstract

MicroRNAs (miRNAs) are small noncoding RNA molecules that regulate protein expression by cleaving or repressing the translation of target mRNAs. In mammal animals, their function mainly represses the target mRNAs transcripts via imperfectly complementary to the 3'UTR of target mRNAs. Several miRNAs have been recently reported to be involved in modulation of glioma development, especially some up-regulated miRNAs, such as microRNA-21 (miR-21), which has been found to function as an oncogene in cultured glioblastoma multiforme cells. Temozolomide (TMZ), an alkylating agent, is a promising chemotherapeutic agent for treating glioblastoma. However, resistance develops quickly and with high frequency. To explore the mechanism of resistance, we found that miR-21 could protect human glioblastoma U87MG cells from TMZ induced apoptosis. Our studies showed that TMZ markedly enhanced apoptosis in U87MG cells compared with untreated cells (P<0.05). However, over-express miR-21 in U87MG cells could significantly reduce TMZ-induced apoptosis (P<0.05). Pro-apoptotic Bax and anti-apoptotic Bcl-2 proteins are known to regulate the apoptosis of glioma cells. Bcl-2, resistance to induction of apoptosis, constitutes one major obstacle to chemotherapy in many cancer cells. Bax is shown to correlate with an increased survival of glioblastoma multiforme patients. Further research demonstrated that the mechanism was associated with a shift in Bax/Bcl-2 ratio and change in caspase-3 activity. Compared to control cells, cells treated with TMZ showed a significant increase in the Bax/Bcl-2 ratio and caspase-3 activity (P<0.01). However, such effect was partly prevented by treatment of cells with miR-21 overexpression before, which appeared to downregulate the Bax expression, upregulate the Bcl-2 expression and decrease caspase-3 activity. Taken together, these results suggested that over-express miR-21 could inhibit TMZ-induced apoptosis in U87MG cells, at least in part, by decreasing Bax/Bcl-2 ratio and caspase-3 activity, which highlighted the possibility of miR-21 overexpression in the clinical resistance to chemotherapeutic therapy of TMZ.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20633539     DOI: 10.1016/j.brainres.2010.07.009

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  122 in total

1.  MicroRNA-21 promotes glioma cell proliferation and inhibits senescence and apoptosis by targeting SPRY1 via the PTEN/PI3K/AKT signaling pathway.

Authors:  Chang Chai; Lai-Jun Song; Shuang-Yin Han; Xi-Qing Li; Ming Li
Journal:  CNS Neurosci Ther       Date:  2018-01-05       Impact factor: 5.243

2.  Nanoparticle-mediated intratumoral inhibition of miR-21 for improved survival in glioblastoma.

Authors:  Young-Eun Seo; Hee-Won Suh; Raman Bahal; Alexander Josowitz; Junwei Zhang; Eric Song; Jiajia Cui; Seth Noorbakhsh; Christopher Jackson; Tom Bu; Alexandra Piotrowski-Daspit; Ranjit Bindra; W Mark Saltzman
Journal:  Biomaterials       Date:  2019-02-14       Impact factor: 12.479

3.  Neuroprotective Role of MicroRNA-22 in a 6-Hydroxydopamine-Induced Cell Model of Parkinson's Disease via Regulation of Its Target Gene TRPM7.

Authors:  Chao Ping Yang; Zhen Hua Zhang; Li Hua Zhang; Han Chen Rui
Journal:  J Mol Neurosci       Date:  2016-09-08       Impact factor: 3.444

4.  Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O⁶-methylguanine methyltransferase and promotes temozolomide responsiveness.

Authors:  Yolande Berthois; Christine Delfino; Philippe Metellus; Frederic Fina; Isabelle Nanni-Metellus; Hayat Al Aswy; Victor Pirisi; L'Houcine Ouafik; Françoise Boudouresque
Journal:  Cancer Biol Ther       Date:  2014-04-22       Impact factor: 4.742

Review 5.  RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Authors:  Eunice L Lozada-Delgado; Nilmary Grafals-Ruiz; Pablo E Vivas-Mejía
Journal:  Life Sci       Date:  2017-08-31       Impact factor: 5.037

6.  Emerging role of microRNA-21 in cancer.

Authors:  Yin-Hsun Feng; Chao-Jung Tsao
Journal:  Biomed Rep       Date:  2016-08-26

7.  Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens.

Authors:  Aysegül Ilhan-Mutlu; Adelheid Wöhrer; Anna Sophie Berghoff; Georg Widhalm; Christine Marosi; Ludwig Wagner; Matthias Preusser
Journal:  J Neurooncol       Date:  2013-02-19       Impact factor: 4.130

Review 8.  Exosomal miRNAs in central nervous system diseases: biomarkers, pathological mediators, protective factors and therapeutic agents.

Authors:  Xiaohuan Xia; Yi Wang; Yunlong Huang; Han Zhang; Hongfang Lu; Jialin C Zheng
Journal:  Prog Neurobiol       Date:  2019-09-19       Impact factor: 11.685

9.  Set9, NF-κB, and microRNA-21 mediate berberine-induced apoptosis of human multiple myeloma cells.

Authors:  Hai-yan Hu; Kun-peng Li; Xiu-ju Wang; Yuan Liu; Zhi-gang Lu; Rui-hong Dong; Hong-bo Guo; Mei-xia Zhang
Journal:  Acta Pharmacol Sin       Date:  2012-12-17       Impact factor: 6.150

10.  Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.

Authors:  Emanuela Leone; Eugenio Morelli; Maria T Di Martino; Nicola Amodio; Umberto Foresta; Annamaria Gullà; Marco Rossi; Antonino Neri; Antonio Giordano; Nikhil C Munshi; Kenneth C Anderson; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Clin Cancer Res       Date:  2013-02-27       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.